Skip to Content

Rule

New Animal Drugs; Change of Sponsor

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Final rule.

SUMMARY:

The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect a change of sponsor for 56 approved new animal drug applications (NADAs) and 3 approved abbreviated new animal drug applications (ANADAs) from Roche Vitamins, Inc., to Alpharma, Inc.

DATES:

This rule is effective September 7, 2001.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

Lonnie W. Luther, Center for Veterinary Medicine (HFV-102), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-0209.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

Roche Vitamins, Inc., 45 Waterview Blvd., Parsippany, NJ 07054-1298, has informed FDA that it has transferred ownership of, and all rights and interest in, the following approved NADAs and ANADAs to Alpharma, Inc., One Executive Dr., P.O. Box 1399, Fort Lee, NJ 07024:

NADA No.Product Name
33-950Sulfamerazine in Fish Grade
35-688Aureo SP-250; Aureomix 500
35-805Aureomix-S 700 Crumbles; Aureomix-S 700
36-361Amprolium Plus Ethopabate/CTC® Sodium Sulfate
40-209Rofenaid® 40
41-647Aureomix-S 700-A
41-648Aureomix-S 700-D
41-649Aureomix-S 700-G
41-650Aureomix-S 700-E
41-651Aureomix-S 700-F
41-652Aureomix-S 700-C-2
41-653Aureomix-S 700-B
41-654Aureomix-S 700-H
41-984Rofenaid® Plus Roxarsone
46-920Baciferm® 10, 25, 40, and 50 Type A Medicated Articles
48-486Robenz® Type A Medicated Article
48-761Aureomycin® Type A Medicated Article
49-287Chlorachel-50
55-040SF Mix 66
92-507Robenz® With Aureomycin® 500
95-546Robenz® Plus Roxarsone
96-298Avatec® and Bovatec® Premixes
96-933Robenz® Plus Zn Bacitracin
97-085Robenz® Plus Bac MD
100-901Pfichlor 100S Milk Replacer Type A Medicated Article
102-485Avatec®/3-Nitro®
105-758Zinc Bacitracin and Amprol HI-E®
107-996Avatec®/Fortracin® Premix
112-661Avatec®/Lincomix®/3-Nitro®
112-687Avatec®/Flavomycin®/3-Nitro®
114-794Baciferm®/Amprol HI-E® Premix
121-553Coban®/Aureomycin®
123-154Coban®/3-Nitro®-10/Baciferm® Premix
125-933Romet®-30 (Sulfamerazine)
126-052Avatec®/Baciferm®/3-Nitro®
128-686Bio-Cox® Type A Medicated Article
131-894Avatec®/Fortracin®/3-Nitro® Broiler Premix
132-447Bio-Cox® Plus Roxarsone
134-185Bio-Cox®/3-Nitro®/Flavomycin®
134-284Bio-Cox®/Flavomycin®
135-321Bio-Cox®/3-Nitro®/BMD®
135-746Bio-Cox®/BMD®
136-484Carb-O-Sep®/Baciferm®
137-536Bio-Cox®/3-Nitro® plus Albac®
137-537Bio-Cox®/Lincomix®
139-075Cygro® Type A Medicated Article
139-190Bio-Cox®/3-Nitro®/Baciferm®
139-235Bio-Cox®/Baciferm®
140-579Bovatec®/Terramycin®
140-581Bio-Cox®/3-Nitro®/Lincomix®
140-859Aureomycin®/Bio-Cox®
140-865Monteban®/Baciferm®
140-867Aureomycin®/Bio-Cox®/3-Nitro®
141-025Cattlyst® Type A Medicated Article
141-109Avatec®/Baciferm®
141-150Avatec®/Stafac®
200-140Aureozol® Type A Medicated Article
200-167Aureozol® 500 Granular
200-242Aureomycin®-50, 70, 80, 90, 100/BMD® 25, 30, 40, 50, 60, 75

Accordingly, the agency is amending the regulations in 21 CFR 558.58, 558.76, 558.78, 558.95, 558.120, 558.128, 558.140, 558.145, 558.155, 558.195, 558.305, 558.311, 558.340, 558.355, 558.363, 558.366, 558.515, 558.550, 558.575, 558.582, and 558.600 to reflect the transfer of ownership. Section 558.95 is also being amended to remove paragraph (d)(1)(x), an entry pertaining to NADA 112-687, which is redundant with § 558.311(e)(1)(ii). Other nonsubstantive changes are being made to remove incorrect drug labeler codes.

This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.

Start List of Subjects

List of Subjects

and 524

End List of Subjects Start Amendment Part

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine,

End Amendment Part Start Part

PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS

End Part

1. The authority citation for 21 CFR part 522 continues to read as follows:

Start Authority

Authority: 21 U.S.C. 360b.

End Authority
[Amended]
Start Amendment Part

2. Section 522.575

End Amendment Part Start Part

PART 524—OPHTHALMIC AND TOPICAL DOSAGE FORM NEW ANIMAL DRUGS

End Part

3. The authority citation for 21 CFR part 524 continues to read as follows:

Start Authority

Start Printed Page 46706 Authority: 21 U.S.C. 360b.

End Authority
[Amended]
Start Amendment Part

4. Section 524.520

End Amendment Part Start Part

PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS

End Part

5. The authority citation for 21 CFR part 558 continues to read as follows:

Start Authority

Authority: 21 U.S.C. 360b, 371.

End Authority
[Amended]
Start Amendment Part

6. Section 558.58

End Amendment Part
[Amended]
Start Amendment Part

7. Section 558.76

End Amendment Part

8. Section 558.78 is amended by revising paragraph (a)(1), by removing paragraph (a)(2), and by redesignating paragraph (a)(3) as paragraph (a)(2); in the table in paragraphs (d)(1)(i) and (d)(1)(ii) under the “Sponsor” column by removing “063238”; and in paragraphs (d)(1)(v) and (d)(1)(vi) under the “Sponsor” column, and in paragraph (d)(2)(ii) by removing “063238” and by adding in its place “046573” to read as follows:

Bacitracin zinc.

(a) * * *

(1) No. 046573: 10, 25, 40, and 50 grams per pound as in paragraph (d) of this section.

* * * * *
[Amended]

9. Section 558.95 Bambermycins is amended by removing and reserving paragraph (d)(1)(x); and in paragraphs (d)(1)(xi) (b), (d)(1)(xii) (b), and (d)(1)(xiv) (b) by removing “063238” and by adding in its place “046573”.

[Amended]

10. Section 558.120 Carbarsone (not U.S.P.) is amended in paragraph (d)(1)(iii) (b) by removing “Nos. 046573 and 063238” and by adding in its place “No. 046573”.

11. Section 558.128 is amended by revising paragraph (a); in the table in paragraph (d)(1) and in paragraph (d)(2) by removing “00004” or “000004” wherever they occur and by adding in their place “046573”; in paragraph (d)(1)(i) in entry 1, and in paragraphs (d)(1)(iv), (d)(1)(vi), and (d)(1)(viii) under the “Sponsor” column by removing “063238” and by adding in its place “046573”; in paragraph (d)(1)(i) in entry 2, and in paragraphs (d)(1)(ii), (d)(1)(iii), (d)(1)(v), (d)(1)(vii), (d)(1)(x), and (d)(1)(xii) in entry 3, and in paragraphs (d)(1)(xiv), (d)(1)(xvi), and (d)(1)(xvii) under the “Sponsor” column by removing “063238” to read as follows:

Chlortetracycline.

(a) Approvals. See sponsors in § 510.600(c) of this chapter for Type A medicated articles containing the following concentrations of either chlortetracycline calcium complex equivalent to chlortetracycline hydrochloride or, for products intended for use in milk replacer, chlortetracycline hydrochloride:

(1) Nos. 000069, 046573, and 053389: 50 to 100 grams per pound.

(2) No. 017519: 50 grams per pound.

* * * * *
[Amended]

12. Section 558.140 Chlortetracycline and sulfamethazine is amended in paragraph (a) by removing “063238” and by adding in its place “046573”.

[Amended]

13. Section 558.145 Chlortetracycline, procaine penicillin, and sulfamethazine is amended in paragraph (a)(1) by removing “and 063238”, and in paragraph (a)(2) by removing “063238” and by adding in its place “046573”.

[Amended]

14. Section 558.155 Chlortetracycline, sulfathiazole, penicillin is amended in paragraph (a)(1) by removing “000004 and 000010” and adding in its place “Nos. 000010 and 046573”, and in paragraph (a)(2) by removing “000004 and 000010” and by adding in its place “000010 and 046573”.

[Amended]

15. Section 558.195 Decoquinate is amended in the table in paragraph (d) in the entry for “Roxarsone 11 to 45 (0.0012-0.005 pct.) plus Bacitracin 12 to 50” under the “Limitations” column by removing “Nos. 011716, 046573, and 063238” and by adding in its place “No. 046573”.

[Amended]

16. Section 558.305 Laidlomycin propionate potassium is amended in paragraph (a) by removing “063238” and by adding in its place “046573”.

[Amended]

17. Section 558.311 Lasalocid is amended in paragraphs (b) and (e) by removing “000004” or “063238” wherever they occur and by adding in their place “046573”.

[Amended]

18. Section 558.340 Maduramicin ammonium is amended in paragraph (a) by removing “063238” and by adding in its place “046573”.

[Amended]

19. Section 558.355 Monensin is amended in paragraphs (b)(8), (b)(9), (f)(1)(iv) (b), and (f)(1)(v) (b) by removing “063238” and by adding in its place “046573”; in paragraphs (f)(1)(xiv) (b) and (f)(1)(xvi) (b) by removing “Nos. 046573 and 063238” and by adding in its place “No. 046573”; and in paragraph (f)(1)(xv) (b) by removing “Nos. 063238 and 046573” and by adding in its place “No. 046573”.

[Amended]

20. Section 558.363 Narasin is amended in paragraphs (a)(7) and (d)(1)(x)(B) by removing “063238” and by adding in its place “046573”.

[Amended]

21. Section 558.366 Nicarbazin is amended in the table in paragraph (c) in the entry for the combination of nicarbazin at 113.5 grams per ton and bacitracin zinc at 4 to 50 grams per ton by removing “063238” in the “Limitations” column and by adding in its place “046573”.

[Amended]

22. Section 558.515 Robenidine hydrochloride is amended in paragraph (a) by removing “063238” and by adding in its place “046573”; in the table in paragraph (d) in the entry for robenidine hydrochloride at 30 grams per ton as a single ingredient by removing “063238” in the “Sponsor” column and by adding in its place “046573”; in the two entries for “Bacitracin (as bacitracin zinc)” by removing “063238” in the “Sponsor” column; and in the entry for “Chlortetracycline 500” by removing “063238” from the “Sponsor” column and by adding in its place “046573”.

Start Printed Page 46707
[Amended]

23. Section 558.550 Salinomycin is amended in paragraph (a)(1) by removing “063238” and by adding in its place “046573”; by removing paragraph (a)(3); in paragraph (d)(1)(xvii)(C) by removing “000004” and by adding in its place “046573”; in paragraphs (d)(1) and (d)(3) by removing “063238” wherever it occurs and by adding in its place “046573”; in paragraph (d)(1)(viii) (c) by removing “(b)(1)(iv) (c)” and by adding in its place “(d)(1)(iv) (c)”; and in paragraph (d)(1)(xi) (c) by removing “(b)(1)(x) (c)” and by adding in its place “(d)(1)(x) (c)”.

[Amended]

24. Section 558.575 Sulfadimethoxine, ormetoprim is amended in paragraphs (a)(1) and (a)(2) by removing “000004” and by adding in its place “046573”.

[Amended]

25. Section 558.582 Sulfamerazine is amended in paragraph (a) by removing “063238” and by adding in its place “046573”.

[Amended]

26. Section 558.600 Tiamulin is amended in paragraph (c)(4)(ii) by removing “046573, 053389, and 063238” and by adding in its place “046573 and 053389”.

Start Signature

Dated: August 24, 2001.

Claire M. Lathers,

Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.

End Signature End Supplemental Information

[FR Doc. 01-22470 Filed 9-6-01; 8:45 am]

BILLING CODE 4160-01-S